Ebola in India: The WHO has declared the Ebola outbreak in Congo and Uganda a public health emergency with over 300 cases and 88 deaths. In...

Moderna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales. The company forecasts lower-tha...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

Merck in November said its full trial results showed that molnupiravir lowered the chance of hospitalization or death by about 30% in patie...

Union health minister Mansukh Mandaviya said 13 companies in India will manufacture the drug approved for restricted use under emergency si...

Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a cl...

If authorized, Merck's pill would be the first that U.S. patients could take at home to ease symptoms and speed recovery, a major step towa...

The new drugs, which unlike vaccines can be used to treat patients once they contract coronavirus infection, are expected to be a huge mark...

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

The two Indian drugmakers, Aurobindo Pharma and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-1...

The trials show that the pill halved the chances of hospitalisation in Covid-19 patients with mild or moderate form of the disease.

The pills are meant for people who are sick with COVID but are not in the hospital.

If cleared, Merck's drug - molnupiravir - would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight ...

In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, incl...

The drugmaker said Monday that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by...

It also announced a partnership with privately-held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-...